Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dual specificity phosphatase 26 (DUSP26) is an atypical member of the protein tyrosine phosphatase family, capable of dephosphorylating both phosphotyrosine and phosphothreonine residues on substrates, notably both MAP kinases and non-MAP kinase proteins such as the tumor suppressor p53[1][3]. DUSP26 contains a non-catalytic N-terminal domain and a catalytic C-terminal domain that features a canonical "HCX5R" active site motif typical for phosphatases; the structure regulates substrate access and enzymatic activity[1][3]. DUSP26 is mostly nuclear, with tissue-restricted expression (notably brain, heart, and skeletal muscle)[1]. It directly modulates key intracellular signaling pathways involved in cell survival, proliferation, and apoptosis—including the MAPK cascade—by dephosphorylating substrates such as ERK, JNK, p38, and p53[1][2][3]. DUSP26 is implicated in a range of diseases, notably with conflicting roles in different cancers: it can function as an oncogene or a tumor suppressor depending on context (e.g., is upregulated in neuroblastoma where it inactivates p53, but downregulated in glioblastoma, acting as a tumor suppressor)[1]. DUSP26 also plays protective roles in cardiac hypertrophy by modulating MAPK pathway activation[2], and contributes to nonalcoholic fatty liver disease regulation by affecting the TAK1–p38/JNK pathway[2]. DUSP26 is a validated research target with small-molecule inhibitors showing proof-of-principle activity in cancer cell studies, but current inhibitors lack specificity for clinical use[1].
Inhibition of DUSP26 enzymatic activity (phosphatase inhibition), leading to increased phosphorylation of target proteins such as p53 or MAPKs[1]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dual specificity phosphatase 26 (DUSP26).